Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833

Article  CAS  PubMed  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379(21):2040–2051

Article  CAS  PubMed  Google Scholar 

Horn L, Mansfield AS, Szczęsna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939

Article  CAS  PubMed  Google Scholar 

Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.N Engl J Med

Marin-Acevedo JA, Kimbrough EO, Lou Y (2021) Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol 14(1):45

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loos M, Hedderich DM, Friess H et al (2010) B7-h3 and its role in antitumor immunity. Clin Dev Immunol 2010:683875

Inamura K, Yokouchi Y, Kobayashi M et al (2017) Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer 103:44–51

Article  PubMed  Google Scholar 

Sun Y, Wang Y, Zhao J et al (2006) B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53(2):143–151

Article  PubMed  Google Scholar 

Benzon B, Zhao SG, Haffner MC et al (2017) Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis 20(1):28–35

Article  CAS  PubMed  Google Scholar 

Brunner A, Hinterholzer S, Riss P et al (2012) Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol Oncol 124(1):105–111

Article  CAS  PubMed  Google Scholar 

Ingebrigtsen VA, Boye K, Tekle C et al (2012) B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer 131(11):2528–2536

Article  CAS  PubMed  Google Scholar 

Scribner JA, Brown JG, Son T et al (2020) Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer. Mol Cancer Ther 19(11):2235–2244

Article  CAS  PubMed  Google Scholar 

Shenderov E, Mallesara G, Wysocki P et al (2021) MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: preliminary results of phase I cohort expansion. Ann Oncol 32 (suppl_5):S626-S677. 610.1016/annonc/annonc1702

Omori S, Muramatsu K, Kawata T et al (2021) Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.J Cancer Res Clin Oncol

Bartley AN, Washington MK, Colasacco C et al (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(4):446–464

Article  CAS  PubMed  Google Scholar 

Yim J, Koh J, Kim S et al (2020) Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer. Eur J Cancer 133:74–85

Article  CAS  PubMed  Google Scholar 

Mao Y, Li W, Chen K et al (2015) B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget 6(5):3452–3461

Article  PubMed  Google Scholar 

Yang Y, Huang JF, Hu BQ et al (2022) B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors. World J Surg Oncol 20(1):159

Article  PubMed  PubMed Central  Google Scholar 

Boland JM, Kwon ED, Harrington SM et al (2013) Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 14(2):157–163

Article  CAS  PubMed  Google Scholar 

Suh WK, Gajewska BU, Okada H et al (2003) The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 4(9):899–906

Article  CAS  PubMed  Google Scholar 

Colonna M, Nakajima H, Cella M (2000) A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin Immunol 12(2):121–127

Article  CAS  PubMed  Google Scholar 

Zhang P, Yu S, Li H et al (2015) ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer. FEBS Lett 589(17):2248–2256

Article  CAS  PubMed  Google Scholar 

Aggarwal C, Prawira A, Antonia S et al (2022) Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.J Immunother Cancer10(4)

Johnson M, Doi T, PihaPaul S et al (2021) A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors. Annals of Oncology 32 (suppl_5):S583-S620. 510.1016/annonc/annonc1699

Doi T, Patel M, Falchook GS et al (2022) 453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: extended follow-up of a phase I/II study. Ann Oncol 33:S744–S745

Article  Google Scholar 

Heymann JJ, Bulman WA, Swinarski D et al (2017) PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol 125(12):896–907

Article  CAS  PubMed  Google Scholar 

Kitazono S, Fujiwara Y, Tsuta K et al (2015) Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer. Clin Lung Cancer 16(5):385–390

Article  CAS  PubMed  Google Scholar 

Ilie M, Long-Mira E, Bence C et al (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27(1):147–153

Article  CAS  PubMed  Google Scholar